Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.
Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data ...
Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.
In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated ...
Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the ...
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 ...
The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.
Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without ...
New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small ...
Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM ...